Climb Bio (CLYM) Competitors $2.33 -0.11 (-4.51%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLYM vs. RLAY, ORGO, TRML, TERN, MGTX, MRVI, ARVN, SIGA, XNCR, and ANABShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include Relay Therapeutics (RLAY), Organogenesis (ORGO), Tourmaline Bio (TRML), Terns Pharmaceuticals (TERN), MeiraGTx (MGTX), Maravai LifeSciences (MRVI), Arvinas (ARVN), Siga Technologies (SIGA), Xencor (XNCR), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Its Competitors Relay Therapeutics Organogenesis Tourmaline Bio Terns Pharmaceuticals MeiraGTx Maravai LifeSciences Arvinas Siga Technologies Xencor AnaptysBio Climb Bio (NASDAQ:CLYM) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends. Which has more risk and volatility, CLYM or RLAY? Climb Bio has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Does the media prefer CLYM or RLAY? In the previous week, Relay Therapeutics had 7 more articles in the media than Climb Bio. MarketBeat recorded 10 mentions for Relay Therapeutics and 3 mentions for Climb Bio. Climb Bio's average media sentiment score of 1.59 beat Relay Therapeutics' score of 0.82 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Relay Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of CLYM or RLAY? 69.8% of Climb Bio shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 0.8% of Climb Bio shares are held by insiders. Comparatively, 4.9% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate CLYM or RLAY? Climb Bio currently has a consensus price target of $9.00, suggesting a potential upside of 286.27%. Relay Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 337.50%. Given Relay Therapeutics' higher possible upside, analysts clearly believe Relay Therapeutics is more favorable than Climb Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Which has preferable earnings & valuation, CLYM or RLAY? Climb Bio has higher earnings, but lower revenue than Relay Therapeutics. Climb Bio is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$73.90M-$0.70-3.33Relay Therapeutics$10.01M68.90-$337.71M-$1.95-2.05 Is CLYM or RLAY more profitable? Climb Bio's return on equity of -23.10% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -23.10% -22.47% Relay Therapeutics N/A -41.49%-37.43% SummaryRelay Therapeutics beats Climb Bio on 8 of the 15 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.34M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E Ratio-3.337.5859.1122.53Price / SalesN/A458.96547.00119.09Price / CashN/A44.5237.0558.92Price / Book0.749.9310.916.06Net Income-$73.90M-$53.38M$3.29B$266.28M7 Day Performance1.30%0.05%0.01%-0.76%1 Month Performance37.06%7.08%7.06%3.83%1 Year PerformanceN/A11.92%50.09%24.39% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio3.4048 of 5 stars$2.33-4.5%$9.00+286.3%N/A$165.34MN/A-3.339News CoveragePositive NewsRLAYRelay Therapeutics2.0177 of 5 stars$3.69+3.4%$17.08+363.0%-36.5%$615.51M$8.36M-1.89330News CoverageAnalyst ForecastORGOOrganogenesis4.2365 of 5 stars$5.12+5.8%$7.50+46.5%+81.7%$613.99M$482.04M-36.57950Positive NewsTRMLTourmaline Bio2.4209 of 5 stars$23.03-2.0%$50.14+117.7%+56.2%$604.15MN/A-6.7144Positive NewsTERNTerns Pharmaceuticals3.9614 of 5 stars$7.07+2.6%$15.63+121.0%+2.9%$602.95MN/A-6.8040News CoveragePositive NewsAnalyst ForecastMGTXMeiraGTx4.5065 of 5 stars$7.49+0.7%$24.00+220.4%+87.5%$598.53M$33.28M-3.67300News CoveragePositive NewsGap UpMRVIMaravai LifeSciences3.7643 of 5 stars$2.38+2.1%$5.22+119.3%-73.0%$594.99M$219.83M-1.75610Positive NewsOptions VolumeARVNArvinas2.8115 of 5 stars$7.76-4.0%$19.76+154.7%-69.0%$593.21M$263.40M-7.68420News CoveragePositive NewsSIGASiga Technologies2.4062 of 5 stars$8.21-0.5%N/A+11.5%$587.89M$179.64M7.2740News CoverageOptions VolumeXNCRXencor3.8192 of 5 stars$8.05+0.4%$23.71+194.6%-50.8%$572.01M$110.49M-3.35280News CoverageAnalyst ForecastANABAnaptysBio2.4406 of 5 stars$20.13-1.3%$46.13+129.1%-37.6%$571.14M$91.28M-4.49100News CoveragePositive News Related Companies and Tools Related Companies Relay Therapeutics Competitors Organogenesis Competitors Tourmaline Bio Competitors Terns Pharmaceuticals Competitors MeiraGTx Competitors Maravai LifeSciences Competitors Arvinas Competitors Siga Technologies Competitors Xencor Competitors AnaptysBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
